Lotonel tablets 5mg, No. 60

edematous syndrome of various origins, incl. with chronic heart failure, diseases of the liver, lungs and kidneys;

arterial hypertension.

Inside, once a day, without chewing, drinking plenty of water. The tablets can be taken at any convenient constant time, regardless of the meal.

Edematous syndrome with CHF. The usual starting dose is 10Ц20 mg once a day. If necessary, the dose can be doubled until the desired effect is obtained.

Edematous syndrome in kidney disease. The usual starting dose is 20 mg once a day. If necessary, the dose can be doubled until the desired effect is obtained.

Edematous syndrome in liver diseases. The usual starting dose is 5-10 mg once a day. If necessary, the dose can be doubled until the desired effect is obtained. The maximum single dose is 40 mg, it is not recommended to exceed it (there is no experience of use). The drug is used for a long period or until the edema disappears.

Arterial hypertension. The initial dose is 2.5 mg (1/2 table. 5 mg) once a day. In the absence of a therapeutic effect within 4 weeks, the dose is increased to 5 mg once a day. In the absence of an adequate decrease in blood pressure when taken at a dose of 5 mg once a day for 4-6 weeks, the dose is increased to 10 mg once a day. If a dose of 10 mg does not give the desired effect, an antihypertensive drug of another group must be added to the treatment regimen.

Elderly patients do not need dose adjustment.

hypersensitivity to torasemide or any of the components of the drug;

allergy to sulfonamides (sulfonamide antimicrobials or sulfonylureas);

renal failure with anuria;

hepatic coma and precoma;

refractory hypokalemia;

refractory hyponatremia;

hypovolemia (with or without arterial hypotension) or dehydration;

pronounced violations of the outflow of urine of any etiology (including unilateral urinary tract damage);

glycosidic intoxication;

acute glomerulonephritis;

sinoatrial and AV blockade of the II Ц III degree;

decompensated aortic and mitral stenosis;

hypertrophic obstructive cardiomyopathy;

increased central venous pressure (over 10 mm Hg);

arrhythmia;

chronic renal failure with increasing azotemia;

hyperuricemia;

simultaneous use of aminoglycosides and cephalosporins;

lactose intolerance, lactase deficiency or glucose-galactose malabsorption;

pregnancy;

breastfeeding period;

age up to 18 years (safety and effectiveness have not been established).

With care: arterial hypotension; stenosing atherosclerosis of the cerebral arteries; hypoproteinemia; violations of the outflow of urine (benign prostatic hyperplasia, narrowing of the urethra or hydronephrosis); history of ventricular arrhythmia; acute myocardial infarction (increased risk of developing cardiogenic shock); diarrhea; pancreatitis; hypokalemia; hyponatremia; liver dysfunction, liver cirrhosis, renal failure, hepatorenal syndrome; diabetes mellitus (decreased glucose tolerance); gout, predisposition to hyperuricemia; anemia; simultaneous use of cardiac glycosides, corticosteroids and ACTH.